StockData
AgomAb Therapeutics NV logo

AgomAb Therapeutics NV (AGMB) stock

AGMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 23, 2026Score 2/30
$5.92−0.05 (-0.84%)

Close on Nov 17, 2026Market cap $148.00KP/E –Yield –

AgomAb Therapeutics total assets

Total assets on the balance sheet at the end of each period.

AgomAb Therapeutics's total assets was €153.71M at Dec 31, 2025. For fiscal 2025 it was €153.71M, down 25.5% from the year before.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025€153.71M-25.5%
FY2024Dec 31, 2024€206.36M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025€153.71M–
Q4 FY2024Dec 31, 2024€206.36M–

More AgomAb Therapeutics figures

See a number that looks wrong?